Nephropathy - Pipeline Review, H1 2016

Published: Apr, 2016 | Pages: 59 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Nephropathy - Pipeline Review, H1 2016

Summary

Global Markets Direct's, ‘Nephropathy - Pipeline Review, H1 2016', provides an overview of the Nephropathy pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Nephropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Nephropathy and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Nephropathy
- The report reviews pipeline therapeutics for Nephropathy by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Nephropathy therapeutics and enlists all their major and minor projects
- The report assesses Nephropathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Nephropathy

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Nephropathy
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Nephropathy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Content
Table of Contents 2

List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Nephropathy Overview 6
Therapeutics Development 7
Pipeline Products for Nephropathy - Overview 7
Nephropathy - Therapeutics under Development by Companies 8
Nephropathy - Pipeline Products Glance 9
Clinical Stage Products 9
Early Stage Products 10
Nephropathy - Products under Development by Companies 11
Nephropathy - Companies Involved in Therapeutics Development 12
Baxalta Incorporated 12
ChemoCentryx, Inc. 13
Complexa, Inc. 14
Omeros Corporation 15
Promedior, Inc. 16
Nephropathy - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Target 18
Assessment by Mechanism of Action 20
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
CCX-168 - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
CXA-10 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
imatinib mesylate - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
OMS-721 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
PRM-151 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
R-190 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
R-801 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
R-901 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
SM-101 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Small Molecule to Inhibit Casein Kinase 2 for Cancer and Nephritis - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Nephropathy - Recent Pipeline Updates 44
Nephropathy - Dormant Projects 56
Nephropathy - Discontinued Products 57
Appendix 58
Methodology 58
Coverage 58
Secondary Research 58
Primary Research 58
Expert Panel Validation 58
Contact Us 58
Disclaimer 59

List of Tables

Number of Products under Development for Nephropathy, H1 2016 7
Number of Products under Development by Companies, H1 2016 8
Comparative Analysis by Clinical Stage Development, H1 2016 9
Comparative Analysis by Early Stage Development, H1 2016 10
Products under Development by Companies, H1 2016 11
Nephropathy - Pipeline by Baxalta Incorporated, H1 2016 12
Nephropathy - Pipeline by ChemoCentryx, Inc., H1 2016 13
Nephropathy - Pipeline by Complexa, Inc., H1 2016 14
Nephropathy - Pipeline by Omeros Corporation, H1 2016 15
Nephropathy - Pipeline by Promedior, Inc., H1 2016 16
Assessment by Monotherapy Products, H1 2016 17
Number of Products by Stage and Target, H1 2016 19
Number of Products by Stage and Mechanism of Action, H1 2016 21
Number of Products by Stage and Route of Administration, H1 2016 23
Number of Products by Stage and Molecule Type, H1 2016 25
Nephropathy Therapeutics - Recent Pipeline Updates, H1 2016 44
Nephropathy - Dormant Projects, H1 2016 56
Nephropathy - Discontinued Products, H1 2016 57